CY1118741T1 - Αναπνευστικος συγκυτιακος ιος με μια γονιδιωματικη ατελεια συμπληρωμενη in trans - Google Patents

Αναπνευστικος συγκυτιακος ιος με μια γονιδιωματικη ατελεια συμπληρωμενη in trans

Info

Publication number
CY1118741T1
CY1118741T1 CY20171100266T CY171100266T CY1118741T1 CY 1118741 T1 CY1118741 T1 CY 1118741T1 CY 20171100266 T CY20171100266 T CY 20171100266T CY 171100266 T CY171100266 T CY 171100266T CY 1118741 T1 CY1118741 T1 CY 1118741T1
Authority
CY
Cyprus
Prior art keywords
virus
pulmonary
trans
viral
viruses
Prior art date
Application number
CY20171100266T
Other languages
English (en)
Inventor
Willem Luytjes
Myra Noorely Widjojoatmodjo
Original Assignee
De Staat Der Nederlanden, Vertegenwoordigd Door De Minister Van Volksgezondheid, Welzijn En Sport
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by De Staat Der Nederlanden, Vertegenwoordigd Door De Minister Van Volksgezondheid, Welzijn En Sport filed Critical De Staat Der Nederlanden, Vertegenwoordigd Door De Minister Van Volksgezondheid, Welzijn En Sport
Publication of CY1118741T1 publication Critical patent/CY1118741T1/el

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • A61K35/76Viruses; Subviral particles; Bacteriophages
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04Inactivation or attenuation; Producing viral sub-units
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/155Paramyxoviridae, e.g. parainfluenza virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08RNA viruses
    • C07K14/115Paramyxoviridae, e.g. parainfluenza virus
    • C07K14/135Respiratory syncytial virus
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5252Virus inactivated (killed)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/54Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541Mucosal route
    • A61K2039/543Mucosal route intranasal
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/18011Paramyxoviridae
    • C12N2760/18511Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18521Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/18011Paramyxoviridae
    • C12N2760/18511Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18522New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/18011Paramyxoviridae
    • C12N2760/18511Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18532Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/18011Paramyxoviridae
    • C12N2760/18511Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/18011Paramyxoviridae
    • C12N2760/18511Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18551Methods of production or purification of viral material
    • C12N2760/18552Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/18011Paramyxoviridae
    • C12N2760/18511Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18561Methods of inactivation or attenuation
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/18011Paramyxoviridae
    • C12N2760/18511Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18561Methods of inactivation or attenuation
    • C12N2760/18562Methods of inactivation or attenuation by genetic engineering

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Η παρούσα εφεύρεση αφορά πνευμονοϊικά βίρια, τα οποία αποτελούνται από ένα ιϊκό γονιδίωμα που έχει μια μετάλλαξη σε ένα γονίδιο που κωδικοποιεί για μια πρωτεΐνη, η οποία είναι ουσιώδης για μολυσματικότητα του πνευμονοϊού, όπου η μετάλλαξη αναγκάζει έναν ιό που παράγεται μόνο από το ιϊκό γονιδίωμα να στερείται μολυσματικότητας, και όπου το βίριο αποτελείται από την πρωτεΐνη σε μια μορφή και σε μια ποσότητα που απαιτείται για τη μολυσματικότητα του βιρίου. Η εφεύρεση αφορά μεθόδους για την παραγωγή των πνευμονοϊικών βιρίων και για τη χρήση των βιρίων στη θεραπευτική αγωγή ή πρόληψη πνευμονοϊικής λοίμωξης και ασθένειας. Ένα προτιμώμενο πνευμονοϊικό βίριο είναι ένα βίριο του Αναπνευστικού Συγκυτιακού Ιού, στο οποίο, κατά προτίμηση, το γονίδιο για την προσάρτηση πρωτεΐνης G απενεργοποιείται και συμπληρώνεται in trans.
CY20171100266T 2003-12-24 2017-02-28 Αναπνευστικος συγκυτιακος ιος με μια γονιδιωματικη ατελεια συμπληρωμενη in trans CY1118741T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NL0300930 2003-12-24
PCT/NL2004/000911 WO2005061698A1 (en) 2003-12-24 2004-12-24 A respiratory syncytial virus with a genomic deficiency complemented in trans

Publications (1)

Publication Number Publication Date
CY1118741T1 true CY1118741T1 (el) 2017-07-12

Family

ID=34709376

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20171100266T CY1118741T1 (el) 2003-12-24 2017-02-28 Αναπνευστικος συγκυτιακος ιος με μια γονιδιωματικη ατελεια συμπληρωμενη in trans

Country Status (24)

Country Link
US (3) US9107939B2 (el)
EP (2) EP2500419B1 (el)
JP (1) JP4814799B2 (el)
KR (1) KR101266715B1 (el)
CN (1) CN1922309B (el)
AU (1) AU2004303719B2 (el)
BR (1) BRPI0418093A (el)
CA (1) CA2551009C (el)
CY (1) CY1118741T1 (el)
DK (1) DK1699919T3 (el)
EA (1) EA011878B1 (el)
ES (2) ES2618523T3 (el)
HK (1) HK1100494A1 (el)
HU (1) HUE032898T2 (el)
IL (1) IL176500A (el)
LT (1) LT1699919T (el)
NO (1) NO334756B1 (el)
NZ (1) NZ548107A (el)
PL (1) PL1699919T3 (el)
PT (1) PT1699919T (el)
SI (1) SI1699919T1 (el)
TR (1) TR201808496T4 (el)
WO (1) WO2005061698A1 (el)
ZA (1) ZA200605218B (el)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201121210D0 (en) * 2011-12-09 2012-01-18 Health Prot Agency Respiratory infection assay
JP6253161B2 (ja) 2012-03-05 2017-12-27 デ スタート デル ネーデルランデン, ヴェルト. ドール デ ミニステル ヴァン ヴイダブリューエス ミニステリー ヴァン ボルクスゲツォントヘイト, ベルジーン エン シュポルトDe Staat Der Nederlanden, Vert. Door De Minister Van Vws Ministerie Van Volksgezondheid, Welzijn En Sport 乾燥された生物学的材料を安定化するための方法及び組成物
AU2014239583B2 (en) 2013-03-14 2020-07-02 Children's Healthcare Of Atlanta, Inc. Recombinant RSV with silent mutations, vaccines, and methods related thereto
KR102219672B1 (ko) 2013-06-17 2021-02-25 드 슈타트 데르 네덜란덴, 베르테겐부어디그트 두어 드 미니스터 반 베이웨이에스, 미니스테리 반 폭스겐트존하이트, 벨지인 엔 스포츠 바이러스 성분의 어그리게이션을 저해하는 방법
US11571472B2 (en) 2014-06-13 2023-02-07 Glaxosmithkline Biologicals Sa Immunogenic combinations
EP3368547A4 (en) 2015-10-29 2019-06-05 Emory University RSV CHIMERIC VIRUSES, IMMUNOGENIC COMPOSITIONS AND METHODS OF USE
WO2017175000A1 (en) * 2016-04-08 2017-10-12 Pulmocide Limited Compounds
CN112746059A (zh) * 2020-09-15 2021-05-04 清华大学 基于病毒结构蛋白遗传互补的冠状病毒细胞模型
CN112501134B (zh) * 2020-12-09 2023-01-20 贵州医科大学附属医院 一种人呼吸道合胞病毒毒株及其应用
CN114990079B (zh) * 2022-04-29 2023-07-04 广州医科大学附属第一医院(广州呼吸中心) 治疗性缺陷干扰颗粒及其在制备用于防治rsv病毒感染的产品中的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0702085T4 (da) 1994-07-18 2010-04-06 Conzelmann Karl Klaus Prof Dr Rekombinant infektiøs ikke-segmenteret negativ-strenget RNA-virus
US5789229A (en) * 1994-09-30 1998-08-04 Uab Research Foundation Stranded RNA virus particles
JPH11512609A (ja) 1995-09-27 1999-11-02 アメリカ合衆国 クローン化されたヌクレオチド配列からの感染性RSウイルス(respiratory syncytial virus)の生産
BR9710363A (pt) 1996-07-15 2000-01-11 Us Gov Health & Human Serv "vìrus sincicial respirátorio recombinante infeccioso isolado, partìcula do mesmo, processos para estimular o sistema imunológico de um indivìduo para induzir proteção contra o vìrus sincicial respiratório e para produzir uma partìcula de vìrus sincicial respiratório recombinante, vacina para induzir proteção contra o vìrus sincicial respiratório recombinante composição e ceta de vìrus sincicial respiratório recombinante"
EP1035205A1 (en) * 1999-03-08 2000-09-13 Stichting Dienst Landbouwkundig Onderzoek Non-spreading pestivirus
DK1297110T3 (da) 2000-06-23 2009-11-16 Intervet Int Bv Attenueret bovin respiratorisk syncytialvirus
WO2003029416A2 (en) 2001-10-01 2003-04-10 Uab Research Foundation Recombinant respiratory syncytial viruses with deleted surface glycoprotein genes and uses thereof

Also Published As

Publication number Publication date
TR201808496T4 (tr) 2018-07-23
HUE032898T2 (hu) 2017-11-28
ZA200605218B (en) 2007-05-30
US9107939B2 (en) 2015-08-18
KR101266715B1 (ko) 2013-05-28
EP1699919A1 (en) 2006-09-13
SI1699919T1 (sl) 2017-07-31
DK1699919T3 (en) 2017-03-20
WO2005061698A1 (en) 2005-07-07
IL176500A0 (en) 2006-10-05
EP2500419B1 (en) 2018-03-21
EP2500419A1 (en) 2012-09-19
CA2551009C (en) 2017-01-17
BRPI0418093A (pt) 2007-04-17
JP2007516721A (ja) 2007-06-28
CN1922309A (zh) 2007-02-28
JP4814799B2 (ja) 2011-11-16
AU2004303719B2 (en) 2010-11-11
US9889168B2 (en) 2018-02-13
CN1922309B (zh) 2011-07-13
ES2618523T3 (es) 2017-06-21
IL176500A (en) 2015-02-26
LT1699919T (lt) 2017-04-25
AU2004303719A1 (en) 2005-07-07
KR20070022210A (ko) 2007-02-26
CA2551009A1 (en) 2005-07-07
HK1100494A1 (en) 2007-09-21
EA011878B1 (ru) 2009-06-30
NO334756B1 (no) 2014-05-19
EP1699919B1 (en) 2017-01-11
US20180207211A1 (en) 2018-07-26
EA200601218A1 (ru) 2006-12-29
NZ548107A (en) 2009-09-25
ES2670713T3 (es) 2018-05-31
US20150329833A1 (en) 2015-11-19
PT1699919T (pt) 2017-04-03
US10967014B2 (en) 2021-04-06
PL1699919T3 (pl) 2017-08-31
US20100291035A1 (en) 2010-11-18
NO20062967L (no) 2006-09-22

Similar Documents

Publication Publication Date Title
CY1118741T1 (el) Αναπνευστικος συγκυτιακος ιος με μια γονιδιωματικη ατελεια συμπληρωμενη in trans
Rezelj et al. The defective component of viral populations
US11466257B2 (en) Cell-derived viral vaccines with low levels of residual cell DNA
Domingo Mechanisms of viral emergence
CY1106848T1 (el) Τροποποιημενος ιος vaccinia ankara για τον εμβολιασμο νεογνων
CY1120558T1 (el) Ενας rdεν3/4δελτα 30(με),rdεν2/4δελτα30(με) ή rdεν1/4δελτα30(με) ανασυνδυασμενος χιμαιρικος ιος του δαγγειου πυρετου ο οποιος περιεχει μια 30 νουκλεοτιδιων διαγραφη (δελτα30) σε ενα τμημα της 3' αμεταφραστης περιοχης του γονιδιωματος ιου του δαγγειου πυρετου τυπου 4, οπου η εν λογω 30 νουκλεοτιδιων διαγραφη αντιστοιχει στην tl2 δομη στελεχους- βροχου
CY1111908T1 (el) Εμβολιο γριπης
DE122011100039I1 (de) DNA-transfektionssystem zur erzeugung von infektiosen negativstrangigen RNA virus.
EA200701695A1 (ru) Рнк вирусы с ослабленной способностью к репликации в качестве вакцин
DE60139026D1 (de) Lebender influenza impfstoff und verfahren zu seiner herstellung
ATE469972T1 (de) Multiplasmid-system zur erzeugung des grippevirus
WO2009050390A3 (fr) Procede de production du virus de la grippe
CY1111552T1 (el) Χρηση hpv16 και hpv18 ως εμβολιο εναντι ενος ή περισσοτερων ογκογονικου hpv τυπου 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68
IS8254A (is) örugg stökkbreytt veirubóluefni
DK1796717T3 (da) Kombinationsvaccine
WO2006136448A3 (en) Attenuated sars and use as a vaccine
Siegel Classification of human viruses
DE60327190D1 (de) Zellen zum nachweis von influenza- und parainfluenzaviren
ME01140B (me) Virus goveđe virusne dijareje s modifikovanim erns proteinom
CY1105704T1 (el) Πρωτεϊνες του πνευμονοϊου ns ανταγωνιζονται την ανταποκριση της ιντερφερονης(ifn)
ATE399210T1 (de) Knockout-mutante von vaccinia-virus und verwendung davon
JP2004501639A5 (el)
AR047581A1 (es) Vacunas de calicivirus felino
DE602005027872D1 (de) Virosomenpartikel mit antigenen aus influenzavirus und hepatitis-b-virus
TW200734463A (en) Marked bovine viral diarrhea virus vaccines